News & Updates

Severe nonadherence to hydroxychloroquine for lupus may have adverse consequences

07 Dec 2023

Among patients receiving hydroxychloroquine for systemic lupus erythematosus (SLE), severe nonadherence to medication poses increased risks of SLE flare in the following year, early damage, and 5-year mortality, according to data from the SLICC* Inception Cohort.

Severe nonadherence to hydroxychloroquine for lupus may have adverse consequences

07 Dec 2023

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

05 Dec 2023 by

For older adults with chronic kidney disease (CKD) who are initiating a disease-modifying antirheumatic drug (DMARD), low-dose methotrexate appears to be associated with a heightened 90-day risk of serious adverse events compared with hydroxychloroquine, as shown in a study.

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

05 Dec 2023

Inflammation, disease duration and delayed diagnosis associated with hypertension in axial spondyloarthritis

05 Dec 2023 by

Axial spondyloarthritis (axSpA) patients with a higher inflammatory burden, longer delay in diagnosis and longer baseline disease duration (BLDD) have an increased risk of developing incident hypertension after adjusting for traditional cardiovascular (CV) risk factors, a retrospective cohort study by the Chinese University of Hong Kong has shown.

Inflammation, disease duration and delayed diagnosis associated with hypertension in axial spondyloarthritis

05 Dec 2023

Avacopan beneficial in ANCA-related vasculitis patients on rituximab

02 Dec 2023

Avacopan, when added to background induction therapy with rituximab, is as efficacious as a prednisone taper in terms of inducing remission at week 26 and is associated with a higher rate of sustained remission at week 52 in patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, according to the phase III ADVOCATE trial.

Avacopan beneficial in ANCA-related vasculitis patients on rituximab

02 Dec 2023

Remibrutinib for Sjögren’s syndrome impresses in phase II trial

16 Nov 2023

The selective potent oral BTK inhibitor remibrutinib has shown favourable efficacy and safety in the treatment of patients with Sjögren’s syndrome, according to the results of a phase II trial.

Remibrutinib for Sjögren’s syndrome impresses in phase II trial

16 Nov 2023

TMJ involvement prevalent in adults with JIA

15 Nov 2023

Clinically established temporomandibular joint (TMJ) involvement occurs frequently in adults with juvenile idiopathic arthritis (JIA), which suggests the need for awareness of TMJ problems in this population, according to a study.

TMJ involvement prevalent in adults with JIA

15 Nov 2023

Residual disease in axSpA more prevalent, severe in female patients

14 Nov 2023

Patients with axial spondyloarthritis (axSpA) who are in a low disease activity (LDA) state or in remission tend to experience residual disease, which occurs more frequently among female patients, reveals a recent study.

Residual disease in axSpA more prevalent, severe in female patients

14 Nov 2023

Which factors predict recurrence of RA-related organizing pneumonia?

14 Nov 2023

The recurrence rate of organizing pneumonia (OP) associated with rheumatoid arthritis (RA) is high, but OP does not appear to contribute to RA exacerbation, suggests a study. Several factors predicting OP recurrence have been identified, such as smoking and lower age at OP onset.

Which factors predict recurrence of RA-related organizing pneumonia?

14 Nov 2023

JAK inhibitor use tied to increased odds of acne

12 Nov 2023

Exposure to Janus kinase (JAK) inhibitors potentially carries an increased likelihood of developing acne, according to a study.

JAK inhibitor use tied to increased odds of acne

12 Nov 2023

Original New Drug Application Approvals by US FDA (16-31 October 2023)

08 Nov 2023

New drug applications approved by US FDA as of 16-31 October 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 October 2023)

08 Nov 2023

News & Updates

Filter by Specialty:

Specialty:

Severe nonadherence to hydroxychloroquine for lupus may have adverse consequences

Severe nonadherence to hydroxychloroquine for lupus may have adverse consequences

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

Inflammation, disease duration and delayed diagnosis associated with hypertension in axial spondyloarthritis

Inflammation, disease duration and delayed diagnosis associated with hypertension in axial spondyloarthritis

Avacopan beneficial in ANCA-related vasculitis patients on rituximab

Avacopan beneficial in ANCA-related vasculitis patients on rituximab

Remibrutinib for Sjögren’s syndrome impresses in phase II trial

Remibrutinib for Sjögren’s syndrome impresses in phase II trial

TMJ involvement prevalent in adults with JIA

TMJ involvement prevalent in adults with JIA

Residual disease in axSpA more prevalent, severe in female patients

Residual disease in axSpA more prevalent, severe in female patients

Which factors predict recurrence of RA-related organizing pneumonia?

Which factors predict recurrence of RA-related organizing pneumonia?

JAK inhibitor use tied to increased odds of acne

JAK inhibitor use tied to increased odds of acne

Original New Drug Application Approvals by US FDA (16-31 October 2023)

Original New Drug Application Approvals by US FDA (16-31 October 2023)